Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Men’s health optimization through peptides spans four major areas: testosterone support, muscle growth and performance, sexual health, and injury recovery. This guide covers six of the most researched peptides for men, organized by goal. Each section includes the compound’s mechanism, research dosing, clinical evidence, and important safety considerations — with accurate data pulled directly from published research.
| Peptide | Primary Goal | Typical Research Dose | Status |
|---|---|---|---|
| Gonadorelin | Testosterone / fertility support | 100–200 mcg, 2–3x/week | Research |
| Kisspeptin-10 | Testosterone / HPG axis | 50–200 mcg, 1–2x daily | Category 1 |
| CJC-1295 | Growth hormone / muscle | 100–300 mcg, 2–3x daily | Category 1 |
| Ipamorelin | Growth hormone / recovery | 200–300 mcg, 2–3x daily | Category 1 |
| PT-141 | Sexual health / desire | 1.75 mg as needed | FDA-Approved |
| BPC-157 | Injury recovery / healing | 250–500 mcg, 1–2x daily | Category 1 |
| TB-500 | Systemic recovery / wound healing | 2–5 mg, 2x/week (loading) | Category 1 |
Peptides that support endogenous testosterone production through the hypothalamic-pituitary-gonadal (HPG) axis.
Also known as: GnRH, LHRH, Factrel, Lutrelef
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH) commonly co-prescribed with testosterone replacement therapy to prevent testicular atrophy and preserve fertility. It has largely replaced hCG in TRT protocols at many hormone clinics following hCG supply constraints. It is also FDA-approved as a diagnostic agent (Factrel) for pituitary function assessment.
Gonadorelin mimics endogenous GnRH, binding to GnRH receptors on pituitary gonadotroph cells to stimulate the release of LH (luteinizing hormone) and FSH (follicle-stimulating hormone). Pulsatile administration maintains the natural hormonal cascade, preventing the testicular atrophy and infertility commonly associated with exogenous testosterone use.
100–200 mcg subcutaneously, 2–3 times per week in TRT support protocols. Pulsatile pump delivery (every 60–120 minutes) more closely mimics physiology and is used in clinical fertility settings. Timing of injections does not need to coincide with testosterone administration.
Clinical use alongside TRT has shown preservation of intratesticular testosterone levels and sperm production. Gonadorelin has been FDA-approved as a diagnostic agent for pituitary function assessment. It maintains HPG axis function during exogenous testosterone use, which is its primary application in men’s health protocols.
Contraindicated in hormone-dependent malignancies (prostate cancer), pregnancy, and ovarian cysts. Side effects include injection site reactions, headache, nausea, flushing, and abdominal discomfort. Should not be used in men with known hypersensitivity to GnRH or its analogs.
Also known as: KP-10, Metastin 45-54, Kisspeptin
Kisspeptin-10 is a truncated fragment of the kisspeptin neuropeptide that plays a central role in reproductive hormone signaling. It is a potent stimulator of GnRH release and is studied for its role in fertility, puberty, and hypogonadism. Research is primarily conducted at academic institutions, including Imperial College London.
Kisspeptin-10 binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamus, triggering the release of gonadotropin-releasing hormone. This cascade stimulates the pituitary to release LH and FSH, driving downstream testosterone production. It acts one step upstream from Gonadorelin in the HPG axis.
SubQ or IV: 50–200 mcg, 1–2 times daily. IV bolus provides rapid but short-lived gonadotropin release. SubQ provides a more sustained response. Often used as a diagnostic challenge test for reproductive axis function in clinical research settings.
Clinical studies demonstrate that kisspeptin administration robustly stimulates LH and FSH release in both men and women. Research shows kisspeptin restores pulsatile LH secretion in patients with signaling deficiencies. It is studied as a diagnostic tool for reproductive disorders and as a potential treatment for male hypogonadism.
Contraindicated in hormone-sensitive cancers (breast, prostate), pregnancy, and pituitary tumors. Side effects include injection site discomfort, flushing, headache, and mild nausea. Less clinical data exists compared to Gonadorelin for practical TRT support use. Its primary applications remain in academic research.
Growth hormone secretagogues that stimulate endogenous GH production for lean mass, recovery, and body composition.
Also known as: CJC-1295 (no DAC), Modified GRF 1-29, Mod GRF
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone secretion. The no-DAC (Drug Affinity Complex) version provides pulsatile GH release that more closely mimics natural physiology and is the version most commonly used in research protocols.
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and secretion of growth hormone. The modified amino acid sequence provides resistance to enzymatic degradation, extending its biological half-life compared to native GHRH. It works synergistically with ghrelin mimetics like Ipamorelin.
100–300 mcg subcutaneously, 2–3 times daily. Best administered on an empty stomach. The no-DAC version requires more frequent dosing than the DAC version but provides more physiological GH pulsatility. Typically combined with Ipamorelin for enhanced efficacy.
Clinical trials have shown CJC-1295 increases GH and IGF-1 levels by 200–1000% without significantly altering other pituitary hormones. It is commonly studied in combination with GHRPs like Ipamorelin for synergistic effects. Research indicates improved body composition, sleep quality, and recovery markers.
Contraindicated in active cancer or tumors, pregnancy, and pituitary disorders. Side effects include flushing, headache, dizziness, injection site reactions, and water retention. Growth hormone elevation may affect blood glucose levels, so monitoring is advisable.
Also known as: IPA
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is considered one of the mildest GHRPs (growth hormone-releasing peptides) with fewer side effects than alternatives like GHRP-6, making it a preferred choice in men’s health optimization protocols.
Ipamorelin mimics ghrelin and binds to the growth hormone secretagogue receptor (GHS-R) in the pituitary gland. Unlike other GHRPs, it does not significantly increase cortisol or prolactin levels, making it more selective in its growth hormone release. This selectivity is what distinguishes it from less targeted GH secretagogues.
200–300 mcg subcutaneously, 2–3 times daily. Best administered on an empty stomach, 30 minutes before or 2 hours after eating. Often stacked with CJC-1295 (no DAC) for enhanced efficacy. Avoid administration close to high-fat meals, which can blunt GH release.
Clinical studies have demonstrated dose-dependent increases in GH release. Ipamorelin has been studied in post-surgical recovery and bone health contexts. It is frequently combined with CJC-1295 for synergistic GH elevation. Research indicates improvements in sleep quality, body composition, and recovery from training.
Contraindicated in active cancer or tumors, pregnancy, and pituitary disorders. Side effects include headache, water retention, tingling or numbness in extremities, and increased hunger. The increased hunger effect is less pronounced than GHRP-6 but still notable in some individuals.
Peptides that address desire, arousal, and sexual function through central nervous system pathways.
Also known as: Bremelanotide, Vyleesi
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist. It was approved in 2019 under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally in the brain rather than peripherally on the vascular system, which differentiates it from PDE5 inhibitors like sildenafil.
PT-141 activates melanocortin-4 receptors (MC4R) in the central nervous system, specifically in the hypothalamus. This activation modulates neural pathways involved in sexual arousal and desire. This is fundamentally different from the vascular mechanism of PDE5 inhibitors, which increase blood flow but do not affect desire.
1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity. Not recommended for use more than once within 24 hours or more than 8 times per month. Blood pressure should be monitored, as transient hypertension is a known effect.
FDA-approved in 2019 based on clinical trials demonstrating statistically significant increases in sexual desire and decreases in distress in premenopausal women with HSDD. Off-label use in men has shown mixed results — some studies indicate pro-erectile effects, while others show more modest outcomes. Phase 1 and 2 trials in men demonstrated dose-dependent sexual arousal effects.
Contraindicated in uncontrolled hypertension, cardiovascular disease, and pregnancy. Nausea is the most common side effect (reported in up to 40% of users). Other side effects include flushing, headache, injection site reactions, and transient hypertension. Concurrent use with naltrexone reduces efficacy.
Tissue-repair peptides that accelerate recovery from training, injuries, and systemic inflammation.
Also known as: Body Protection Compound-157, Bepecin
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most widely studied peptides for tissue healing, with extensive preclinical evidence for accelerating repair of tendons, ligaments, muscles, and the gastrointestinal tract — making it particularly relevant for active men dealing with training-related injuries.
BPC-157 upregulates growth factor expression including VEGF, EGF, and the FAK-paxillin pathway, promoting angiogenesis and tissue granulation. It also modulates nitric oxide synthesis and interacts with the dopaminergic system to exert cytoprotective effects.
250–500 mcg subcutaneously, 1–2 times daily. Injection near the injury site is the most common approach. Oral dosing is used for GI-related applications. Cycles of 4–6 weeks on, 2 weeks off are typical.
Extensive preclinical research demonstrates accelerated healing of tendons, ligaments, muscles, and the GI tract. Studies show enhanced growth hormone receptor expression in tendon fibroblasts. Human clinical trials are limited but underway. It remains one of the most researched peptides in regenerative medicine.
Contraindicated in active cancer or history of cancer due to angiogenesis promotion. Side effects include nausea (especially oral), dizziness, injection site irritation, and headache. Category 1 regulatory status may affect pharmacy availability.
Also known as: Thymosin Beta-4, TB4
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration, proliferation, and differentiation. It is studied for wound healing, tissue repair, and reduction of inflammation. It is often combined with BPC-157 in recovery protocols.
TB-500 promotes cell migration by upregulating actin, a cell-building protein critical for cell motility and structure. It reduces inflammation via downregulation of pro-inflammatory cytokines and supports new blood vessel formation at injury sites. Its systemic mechanism means it does not require injection near the injury.
Loading phase: 2–5 mg subcutaneously, 2 times per week for 4–6 weeks. Maintenance: once weekly. Can be injected anywhere subcutaneously. Often combined with BPC-157 for comprehensive recovery support.
Animal studies show significant benefits in wound healing, cardiac repair post-infarction, and corneal repair. TB-500 has been used extensively in equine veterinary medicine for injury recovery. Clinical trials in humans are limited. It is one of the most commonly used recovery peptides in athletic and men’s health contexts.
Contraindicated in active cancer due to promotion of angiogenesis and cell migration. Side effects include headache, lethargy, injection site pain, and temporary head rush. TB-500 is dosed in milligrams (not micrograms like BPC-157), making it a higher-volume injection.
Many men’s health protocols address multiple goals simultaneously. Here are common combinations seen in research contexts. Any multi-compound protocol should be developed with a qualified healthcare provider.
Testosterone + GH Optimization
Gonadorelin + CJC-1295/Ipamorelin
This combination supports both endogenous testosterone production (via HPG axis stimulation) and growth hormone output (via GHRH/ghrelin pathways). Gonadorelin preserves fertility during TRT while the GH secretagogue stack supports body composition, recovery, and sleep quality.
Performance + Recovery
CJC-1295/Ipamorelin + BPC-157
The GH secretagogue stack supports lean mass and overall recovery, while BPC-157 targets specific injury sites. This is a common approach for active men managing both performance goals and musculoskeletal injuries.
Comprehensive Men’s Health
Gonadorelin + CJC-1295/Ipamorelin + BPC-157/TB-500
The most comprehensive approach addresses testosterone preservation, growth hormone optimization, and tissue recovery simultaneously. This level of complexity requires careful medical oversight, baseline labs, and ongoing monitoring.
Gonadorelin and Kisspeptin-10 are the two most studied peptides for supporting endogenous testosterone production. Gonadorelin is the more commonly used option, particularly alongside TRT to preserve fertility and prevent testicular atrophy. Kisspeptin-10 acts upstream, stimulating GnRH release from the hypothalamus. Both work through the HPG axis rather than introducing exogenous testosterone.
In some cases, peptides like Gonadorelin and Kisspeptin-10 may support endogenous testosterone production enough to address mild hypogonadism without exogenous testosterone. However, for men with significant testosterone deficiency, these peptides are more commonly used alongside TRT — not as replacements. Gonadorelin in particular is frequently co-prescribed with TRT to maintain fertility and prevent testicular atrophy.
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (brand name Vyleesi). Off-label use in men has shown mixed results in clinical studies. It works through melanocortin-4 receptors in the brain to modulate sexual arousal — a different mechanism than PDE5 inhibitors like sildenafil. Common side effects include nausea (up to 40%), flushing, and transient hypertension.
CJC-1295 (no DAC) and Ipamorelin are frequently combined because they stimulate growth hormone through complementary mechanisms. CJC-1295 is a GHRH analog that stimulates GH synthesis, while Ipamorelin is a ghrelin mimetic that triggers GH release. Together, they produce synergistic GH elevation. Clinical trials have shown CJC-1295 increases GH and IGF-1 by 200–1000%. The combination is typically administered 2–3 times daily on an empty stomach.
Each peptide has its own safety profile. FDA-approved PT-141 has undergone extensive clinical trials. Gonadorelin has been FDA-approved as a diagnostic agent with a well-characterized safety profile. CJC-1295 and Ipamorelin have clinical trial data supporting their use. BPC-157 and TB-500 have extensive preclinical data but limited human trials. All compounds have contraindications and potential side effects. Consult a licensed healthcare provider before use.
Growth hormone secretagogues like CJC-1295 and Ipamorelin stimulate endogenous GH production, which supports lean mass, recovery, and body composition. They do not produce the dramatic muscle-building effects of anabolic steroids — they work by optimizing natural GH output. Research suggests benefits for body composition, sleep quality, and recovery from training. They are best understood as recovery and optimization tools rather than anabolic agents.
Research protocols often address multiple goals simultaneously — for example, combining a GH secretagogue stack (CJC-1295/Ipamorelin) for recovery and body composition with Gonadorelin for testosterone support. However, combining multiple compounds increases complexity and the potential for interactions. Any multi-peptide protocol should be developed with a qualified healthcare provider.
Both support testosterone production through the HPG axis, but at different levels. Gonadorelin is synthetic GnRH that directly stimulates LH and FSH release from the pituitary. Kisspeptin-10 acts one step upstream — it stimulates GnRH neurons in the hypothalamus, which then trigger the pituitary cascade. Gonadorelin is more widely used in clinical TRT protocols, while Kisspeptin-10 is primarily studied in academic research settings.
Use our free tools to compare prices, calculate reconstitution doses, and build research protocols.
Hormone Optimization Stack
Pre-built testosterone protocol
Sexual Health Stack
Pre-built sexual wellness protocol
Hormone Peptides
Browse all hormone compounds
Muscle Growth Guide
Deep dive on muscle-building peptides
Reconstitution Calculator
Calculate your exact dose
Build a Protocol
Create a custom research protocol
This platform provides informational tools only, not medical advice. Consult a licensed provider.
This guide is for educational purposes only. It is not medical advice. Consult a licensed healthcare provider before using any peptide.
Disclosed Labs